Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and
 vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic
 dermatitis.
Inclusion Criteria:

 -  Adolescent or adult subject aged 12 - 65 years.

 -  Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA

 Exclusion Criteria:

 -  AD with known hypersensitivity to excipients of TER-101 Ointment

 -  Subjects who are immunocompromised